Full Breakdown
Trump Administration Strikes Deals to Lower Prices of Weight Loss Drugs
11/7/2025, 12:43:37 AM
Overview of the Agreements
On November 6, 2025, President Donald Trump announced significant agreements with pharmaceutical companies Eli Lilly and Novo Nordisk aimed at reducing the costs of their popular weight loss drugs, Zepbound and Wegovy. These glucagon-like peptide-1 (GLP-1) medications, previously priced over $1,000 per month, will now be available for as low as $149 for starting doses of new oral formulations and approximately $350 for injectable versions. The agreements are part of Trump's broader initiative to lower drug prices in the United States.
Key Details of the Pricing Structure
Under the new arrangements, Medicare will begin covering GLP-1 drugs for obesity for the first time, with eligible patients paying a copay of $50 per month. The average price for these medications will be reduced to $245 for Medicare, with the expectation that prices will further decrease to about $250 over the next two years. The agreements also stipulate that state Medicaid programs can opt into these pricing structures, potentially broadening access for low-income patients.
Eligibility Criteria for Medicare Coverage
Medicare beneficiaries will qualify for coverage based on specific health criteria. Those with a body mass index (BMI) greater than 27, individuals with obesity (BMI over 30) who also have conditions like uncontrolled hypertension or heart failure, and patients with severe obesity (BMI over 35) will be eligible for the reduced pricing. This expansion is expected to benefit approximately 10% of Medicare enrollees.
Impact on Drug Accessibility
The Trump administration's initiative, branded as TrumpRx, is set to launch in early 2026, allowing consumers to purchase these medications directly at discounted prices. The administration has emphasized that this move will democratize access to essential medications and potentially lead to significant health improvements across the population. Health Secretary Robert F. Kennedy Jr. projected that the public could collectively lose 125 million pounds within a year due to increased access to these drugs.
Official Statements & Responses
In his announcement, Trump described the agreements as a "triumph for American patients that will save lives and improve the health of millions." Eli Lilly's CEO, David A. Ricks, stated that the deal represents a pivotal moment in U.S. healthcare policy, while Novo Nordisk's CEO, Mike Doustdar, highlighted the importance of expanding patient access and affordability.
Criticism & Opposition
Despite the optimistic outlook, some healthcare professionals have expressed cautious optimism. Dr. Kimberly Guzman, medical director for the American Board of Obesity Medicine, noted the previous frustrations patients faced regarding the affordability of effective weight loss medications. Critics have also pointed out that while the agreements expand access, they do not guarantee comprehensive coverage for all individuals with obesity, as many private insurers still do not cover these medications for weight loss.
Conflicting Reports & Gaps
While the Trump administration has projected significant savings and health benefits from these agreements, the actual impact on consumers remains uncertain. Variations in insurance coverage and market competition may affect how much individuals ultimately save. Additionally, the Biden administration had previously proposed expanding Medicare coverage for obesity medications, but those plans were halted by the Trump administration, raising questions about the long-term sustainability of these new agreements.
What's Next
As the TrumpRx platform prepares for launch, the administration is expected to continue negotiating with pharmaceutical companies to further reduce drug prices. The upcoming approvals of new oral GLP-1 medications will also be closely monitored, as they could significantly alter the landscape of obesity treatment in the United States.
